Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting for the Treatment of Left Main Coronary Artery Disease
- Author:
Sang Cheol CHO
1
;
Duk Woo PARK
;
Seung Jung PARK
Author Information
- Publication Type:Review
- Keywords: Coronary artery disease; Percutaneous coronary intervention; Coronary artery bypass; Angioplasty, balloon, coronary; Drug-eluting stents; Treatment outcome
- MeSH: Angioplasty, Balloon, Coronary; Atherosclerosis; Constriction, Pathologic; Coronary Artery Bypass; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Humans; Mortality; Myocardial Infarction; Myocardium; Percutaneous Coronary Intervention; Stents; Stroke; Treatment Outcome
- From:Korean Circulation Journal 2019;49(5):369-383
- CountryRepublic of Korea
- Language:English
- Abstract: Severe stenosis of the left main coronary artery (LMCA) generally occurs as a result of atherosclerosis and compromises the blood supply to a wide area of myocardium, thereby increasing the risk of serious adverse cardiac events. Current revascularization strategies for patients with significant LMCA disease include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), both of which have a range of advantages and disadvantages. In general, PCI is associated with a lower rate of periprocedural adverse events and provides more rapid recovery, while CABG provides more durable revascularization. Most clinical trials comparing PCI and CABG for the treatment of LMCA disease have shown PCI to be non-inferior to CABG with respect to mortality and the serious composite outcome of death, myocardial infarction, or stroke in patients with low-to-intermediate anatomical complexities. Remarkable advancements in PCI standards, including safer and more effective stents, adjunctive intravascular imaging or physiologic evaluation, and antithrombotic treatment, may have contributed to these favorable results. This review provides an update on the current management of LMCA disease with an emphasis on clinical data and academic and clinical knowledge that supports the use of PCI in an increasing proportion of patients with LMCA disease.
